Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C

References

• Pipe S. Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. Biologics. 2009;3:117–125. doi:10.2147/btt.2009.2872
   PubMedGoogle Scholar
• Srivastava A, Brewer A, Mauser-Bunschoten E, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.
   PubMed Web of Science ®Google Scholar
• Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life FVIII/IX concentrates. J Clin Med. 2017;6(4):39. doi:10.3390/jcm6040039
   PubMed Web of Science ®Google Scholar
• Advate [prescribing information]. Baxter Healthcare Corporation; 2011. Available from: https://www.fda.gov/downloads/BloodBloodProducts/ucm059095.pdf. Accessed September 18, 2018.
   Google Scholar
• Kogenate [summary of product characteristics]. Bayer HealthCare Manufacturing SRL; 2018. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000275/human_med_000879.jsp&mid=WC0b01ac058001d124. Accessed September 28, 2018.
   Google Scholar
• NUWIQ [prescribing information]. Octapharma AB; 2015. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM461328.pdf. Accessed September 28, 2018.
   Google Scholar
• NovoEight® [summary of product characteristics]. Novo Nordisk A/S; 2018. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002719/WC500157553.pdf. Accessed August 23, 2018.
   Google Scholar
• NovoEight®. [Highlights of prescribing information]. Available from: https://www.novo-pi.com/novoeight.pdf. Accessed August 10, 2018.
   Google Scholar
• Jivi [summary of product characteristics]. Bayer AG; 2019. Available from: https://www.ema.europa.eu/en/documents/product-information/jivi-epar-product-information_en.pdf. Accessed November 14, 2019.
   Google Scholar
• ELOCTATE [summary of product characteristics]. Swedish Orphan Biovitrum AB; 2019. Available from: https://www.ema.europa.eu/en/documents/product-information/elocta-epar-product-information_en.pdf. Accessed November 14, 2019.
   Google Scholar
• ADYNOVATE [package insert]. Baxalta US Inc; 2019. Available from: https://www.fda.gov/files/vaccines,%20blood%20&%20biologics/published/Package-Insert—ADYNOVATE.pdf. Accessed November 14, 2019.
   Google Scholar
• AFSTYLA [summary of product characteristics]. CSL Behring GmBH; 2019. Available from: https://www.ema.europa.eu/en/documents/product-information/afstyla-epar-product-information_en.pdf. Accessed November 14, 2019.
   Google Scholar
• ESPEROCT. [Summary of product characteristics]. Available from: https://www.ema.europa.eu/en/documents/product-information/esperoct-epar-product-information_en.pdf. Accessed 14 November 2019.
   Google Scholar
• ESPEROCT [package insert]. Novo Nordisk A/S; 2019. Available from: https://www.fda.gov/media/120351/download. Accessed November 14, 2019.
   Google Scholar
• Tischer B, Marino R, Napolitano M. Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Prefer Adherence. 2018;12:431–441. doi:10.2147/PPA.S151812
   PubMed Web of Science ®Google Scholar
• DiBenedetti D, Coles T, Sharma T, Pericleous L, Kulkarni R. Assessing patients’ and caregivers’ perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. Haemophilia. 2014;20(4):e296–e303. doi:10.1111/hae.12459
   Web of Science ®Google Scholar
• Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med. 2013;4:49–56. doi:10.2147/JBM.S43734
   PubMedGoogle Scholar
• Shannon E, Daffy J, Jones H, Paulson A, Vicik SM. Etanercept (Enbrel) alternative storage at ambient temperature. Clin Pharmacol. 2017;9:87–99. doi:10.2147/CPAA.S131832
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO Technical Report Series 953; forty-third report; 2009. Available from: http://apps.who.int/iris/bitstream/handle/10665/44553/WHO_TRS_953_eng.pdf?sequence=1. Accessed November 1, 2018.
   Google Scholar
• Kulkarni R, Karim F, Glamocanin S, et al. Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. 2013;19(5):698–705. doi:10.1111/hae.12165
   PubMed Web of Science ®Google Scholar
• Santagostino E, Lentz SR, Misgav M, et al. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian clinical trials. Haemophilia. 2015;21(1):34–40. doi:10.1111/hae.12518
   PubMed Web of Science ®Google Scholar
• Lentz S, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013;19(5):691–697. doi:10.1111/hae.12159
   PubMed Web of Science ®Google Scholar
• Curry N, Albayrak C, Escobar M, et al. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: safety and efficacy results from pathfinder 2 (randomized Phase III trial). Haemophilia. 2019;25(3):373–381. doi:10.1111/hae.13712
   Web of Science ®Google Scholar
• Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(2):252–261. doi:10.1160/TH16-06-0444
   PubMed Web of Science ®Google Scholar
• Hampton K, Chowdary P, Dunkley S, et al. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A. Haemophilia. 2017;23(5):689–696. doi:10.1111/hae.13246
   Web of Science ®Google Scholar
• Meunier S, Alamelu J, Ehrenforth S, et al. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017;117(9):1705–1713. doi:10.1160/TH17-03-0166
   PubMed Web of Science ®Google Scholar
• Stennicke HR, Kjalke M, Karpf DM, et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood. 2013;121(11):2108–2116. doi:10.1182/blood-2012-01-407494
   PubMed Web of Science ®Google Scholar
• Ellgaard TW, Bindslev L, Kamstrup S. Evaluation of the virus clearance capacity and robustness of the manufacturing process for the recombinant factor VIII protein, turoctocog alfa. Protein Expr Purif. 2017;129:94–100. doi:10.1016/j.pep.2016.09.002
   PubMed Web of Science ®Google Scholar
• Agerso H, Stennicke HR, Pelzer H, et al. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia. 2012;18(6):941–947. doi:10.1111/j.1365-2516.2012.02896.x
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: quality of Biotechnological Products: stability Testing of Biotechnological/Biological Products Q5C. Current Step 5 version. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-topic-q-5-c-quality-biotechnological-products-stability-testing-biotechnological/biological-products_en.pdf. Accessed May 19, 2020.
   Google Scholar
• European Pharmacopoeia. 10th Edition. Available from: https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-10th-edition. Accessed May 19, 2020.
   Google Scholar
• Eldin A, Shalaby A. Comparison of FT-NIR transmission and HPLC to assay montelukast in its pharmaceutical tablets. Am J Analytical Chem. 2011;2(8):885–891. doi:10.4236/ajac.2011.28102.
   Google Scholar
• Wang W, Wang YJ, Kelner DN. Coagulation factor VIII: structure and stability. Int J Pharm. 2003;259(1–2):1–15. doi:10.1016/S0378-5173(03)00227-8
   Web of Science ®Google Scholar
• Butenas S, Parhami-Seren B, Gissel MT, Gomperts ED, Fass DN, Mann KG. Potency and mass of factor VIII in FVIII products. Haemophilia. 2009;15(1):63–72. doi:10.1111/j.1365-2516.2008.01826.x
   Web of Science ®Google Scholar
• Yoshioka S, Aso Y. Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals. J Pharm Sci. 2007;96(5):960–981. doi:10.1002/jps.20926
   PubMed Web of Science ®Google Scholar
• Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8(3):E501–507. doi:10.1208/aapsj080359
   PubMed Web of Science ®Google Scholar
• Napolitano M, Nohr AM. The effect of fluctuating temperature on the stability of turoctocog alfa for hemophilia A. Drugs R D. 2019;19(4):381–390. doi:10.1007/s40268-019-00290-3
   PubMed Web of Science ®Google Scholar
• Novais T, Duclos A, Varin R, Lopez I, Chamouard V. Treatment-related knowledge and skills of patients with haemophilia and their informal caregivers. Int J Clin Pharm. 2016;38(1):61–69. doi:10.1007/s11096-015-0207-z
   Web of Science ®Google Scholar
• Parti R, Ardosa J, Yang L, Mankarious M. In vitro stability of recombinant human factor VIII (Recombinate). Haemophilia. 2000;6(5):513–522. doi:10.1046/j.1365-2516.2000.00410.x
   Web of Science ®Google Scholar
• Parti R, Schoppmann A, Lee H, Yang L. Stability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHF-PFM). Haemophilia. 2005;11(5):492–496. doi:10.1111/j.1365-2516.2005.01128.x
   Web of Science ®Google Scholar